Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5594461 | American Heart Journal | 2017 | 9 Pages |
Abstract
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Valentina MD, PhD, Christopher PhD, Mary W. MS, David MD, James MD, Mark MD, Henry MD, Ilan MD, Stephen MD, PhD, David MD, Helmut MD, Reinoud MD, PhD, Mikhail MD, PhD, Jeanne MD, Claudio MD, Jagmeet P. MD, PhD, Scott MD, David MD, Arthur J. MD,